Press center

| Investor News

Beauty segment: growth and profitability increased again

  • Revenue: +11.0% to EUR 56.9 million (H1 2025: EUR 51.2 million)
  • EBIT: +23.8% to EUR 18.6 million (H1 2025: EUR 15.0 million)
  • EBIT margin: 32.7% (H1 2025: 29.4%)

Key Group figures:

  • Group revenue: EUR 76.6 million (H1 2025: EUR 183.5 million)
  • EBITDA: EUR 17.7 million (H1 2025: EUR 20.5 million)
  • EBIT: EUR 15.6 million (H1 2025: EUR 18.0 million)
  • EBIT margin: 20.4% (H1 2025: 9.8%)
  • EBT: EUR 16.0 million (H1 2025: EUR 16.9 million)
  • Earnings per share: EUR 0.52 (H1 2025: EUR 0.63)

Beauty segment: profitability again significantly increased

  • Revenue: +5.7% to EUR 27.1 million (Q1 2025: EUR 25.6 million)
  • EBIT: +37.6% to EUR 9.2 million (Q1 2025: EUR 6.7 million)
  • EBIT margin: 33.9% (Q1 2025: 26.0%)

Group figures: shaped by the sale of HAEMATO Pharm GmbH

  • Group revenue: EUR 46.8 million (Q1 2025: EUR 92.7 million)
  • EBIT: EUR 5.0 million (Q1 2025: EUR 8.8 million)

| Investor News

M1 Kliniken AG (ISIN DE000A0STSQ8) has cancelled the treasury shares acquired under its share buyback programme and reduced its share capital accordingly.

On 25 March 2026, the Management Board resolved, with the approval of the Supervisory Board granted on 26 March 2026 and on the basis of the authorisation by the Annual General Meeting of 17 July 2024, to reduce the Company's share capital by EUR 1,088,289 from EUR 19,643,403 to EUR 18,555,114. The capital reduction became effective upon registration in the commercial register of the Local Court of Charlottenburg (HRB 107637 B) on 26 May 2026.

Press contact

Press contact

Grünauer Straße 5
12557 Berlin
Germany

T. +49 (0) 30 347 47 44 14